Boehringer Ingelheim Venture Fund — 2018 Investments
2 investments dated 2018 · listed companies and verified rows first · show all
Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing.
BiotechDigital HealthHealthtechMedical DevicesTübingen, DE
Hubert Löwenheim(Founder / Board Member)
Co-investorsKfWCreathor VenturesLBBW Venture Capital GmbHEsperante Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

